Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Monopar Therapeutics changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 8 | 14 | +6 |
| Shares | 192.4K | 301.4K | +109.0K (+56.6%) |
| Value | $164.5K | $182.2K | +$17.7K (+10.7%) |
New holders (7)
Institutions that held Monopar Therapeutics at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Windsor Advisory Group, LLC | 89,974 | $55.8K | 0.13% |
| Two Sigma Securities, LLC | 24,663 | $15.3K | 0.00% |
| HRT Financial LP | 13,078 | $7.00K | 0.00% |
| Susquehanna International Group, LLP | 10,461 | $5.96K | 0.00% |
| Federation des caisses Desjardins du Quebec | 80 | $50 | 0.00% |
| UBS Group AG | 72 | $45 | 0.00% |
| JPMorgan Chase & Co | 4 | $2 | 0.00% |
Sold out (1)
Institutions that held Monopar Therapeutics at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| FMR LLC | 150 | $128 |